Azelnidipine structure 
             | 
        Common Name | Azelnidipine | ||
|---|---|---|---|---|
| CAS Number | 123524-52-7 | Molecular Weight | 582.646 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 709.3±60.0 °C at 760 mmHg | |
| Molecular Formula | C33H34N4O6 | Melting Point | 120-126ºC | |
| MSDS | Chinese USA | Flash Point | 382.8±32.9 °C | |
| Symbol | 
             
            
             
            
            GHS05, GHS07  | 
        Signal Word | Danger | |
            Use of AzelnidipineAzelnidipine(CS 905; Calblock) is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive.IC50 value:Target: L-type calcium channelAcute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis.  | 
    
| Name | Azelnidipine | 
|---|---|
| Synonym | More Synonyms | 
| Description | Azelnidipine(CS 905; Calblock) is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive.IC50 value:Target: L-type calcium channelAcute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis. | 
|---|---|
| Related Catalog | |
| References | 
| Density | 1.3±0.1 g/cm3 | 
|---|---|
| Boiling Point | 709.3±60.0 °C at 760 mmHg | 
| Melting Point | 120-126ºC | 
| Molecular Formula | C33H34N4O6 | 
| Molecular Weight | 582.646 | 
| Flash Point | 382.8±32.9 °C | 
| Exact Mass | 582.247864 | 
| PSA | 139.71000 | 
| LogP | 4.21 | 
| Vapour Pressure | 0.0±2.3 mmHg at 25°C | 
| Index of Refraction | 1.659 | 
| Storage condition | Room temp | 
                                    CHEMICAL IDENTIFICATION
 
 
 
 
 
 
 HEALTH HAZARD DATAACUTE TOXICITY DATA
 
 
 
 
 
  | 
                            
| Symbol | 
                                    
                                     
                                    
                                     
                                    
                                    GHS05, GHS07  | 
                            
|---|---|
| Signal Word | Danger | 
| Hazard Statements | H302-H318 | 
| Precautionary Statements | P280-P305 + P351 + P338 | 
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves | 
| Hazard Codes | Xn | 
| Risk Phrases | R22 | 
| Safety Phrases | 26-39 | 
| RIDADR | NONH for all modes of transport | 
| RTECS | US7968332 | 
| HS Code | 2933990090 | 
| HS Code | 2933990090 | 
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% | 
| 
                                    
                                    Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
                                    
                                    
                                     Tohoku J. Exp. Med. 228 , 305-315, (2012) Many studies have aimed to identify anti-atherogenic agents in cardiovascular medicine. We have recently demonstrated that the combination therapy with olmesartan (OLM), an angiotensin II receptor blo...  | 
                                |
| 
                                    
                                    The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
                                    
                                    
                                     J. Cardiovasc. Pharmacol. 61(1) , 63-9, (2013) We examined antianginal effects of azelnidipine and amlodipine in an arginine vasopressin-induced rat anginal model. Oral administration of azelnidipine or amlodipine produced long lasting inhibition ...  | 
                                |
| 
                                    
                                    Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.
                                    
                                    
                                     Cardiovasc. Diabetol. 10 , 97, (2011) Numerous evidences suggest that diabetic heart is characterized by compromised ventricular contraction and prolonged relaxation attributable to multiple causative factors including calcium accumulatio...  | 
                                
| Azelnidipine | 
| 3-[1-(Diphenylmethyl)-3-azetidinyl] 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate | 
| 3-[1-(Diphenylmethyl)azetidin-3-yl] 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | 
| UNII:PV23P19YUG | 
| 3,5-Pyridinedicarboxylic acid (2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl) | 
| 3-[1-(diphenylmethyl)azetidin-3-yl] 5-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | 
| 3-O-(1-benzhydrylazetidin-3-yl) 5-O-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | 
| (±)-1,4-Dihydro-2-amino-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-(1-(Diphenylmethyl)-3-azetidinyl) 5-(1-Methylethyl) Ester | 
| 3,5-Pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) ester | 
| 3-(1-(Diphenylmethyl)-3-azetidinyl) 5-Isopropyl (±)-2-Amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate | 
| MFCD00865803 |